Loading
A phase 1 trial of BPX-601 run by Regeneron Pharmaceuticals, terminated.
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors is a phase 1 interventional study registered as NCT02744287 by Regeneron Pharmaceuticals, with 52 participants enrolled, started 2016-11-30. Conditions recorded: Metastatic Castration-resistant Prostate Cancer and Metastatic Prostate Cancer. Interventions recorded: BPX-601 and Rimiducid.
Shares BPX-601, Bellicum Pharmaceuticals, Regeneron, Prostate cancer and the tag pipeline.
Shares Regeneron, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/